Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study

Concomitant Use of Analgesics and EGFR TKIs in Lung Cancer Patients: Outcomes and Perspectives From a Finnish Retrospective Register–Based Study

ABSTRACT Introduction Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used in the treatment of non‐small cell lung cancer (NSCLC). Preclinical studies suggest inflammatory and other mechanisms of analgesics affect the efficacy of EGFR TKIs. In this study, we aim to expl...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura S. Puuniemi, Sanna M. E. Iivanainen, Martti Arffman, Riitta L. Kaarteenaho, Jussi P. Koivunen
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Cancer Medicine
Subjects:
EGFR TKI
NSAID
NSCLC
opioid
Online Access:https://doi.org/10.1002/cam4.71040
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.71040

Similar Items